N Engl J Med | Dr. Jun Shi’s Team Reports First Successful Use of BCMA-Targeted Bispecific T-Cell Engager to Rescue Relapsed Autoimmune Hemolytic Anemia After CD19 CAR T-Cell Therapy

N Engl J Med | Dr. Jun Shi’s Team Reports First Successful Use of BCMA-Targeted Bispecific T-Cell Engager to Rescue Relapsed Autoimmune Hemolytic Anemia After CD19 CAR T-Cell Therapy

2025.06.13
Autoimmune hemolytic anemia (AIHA) has a relatively high incidence (1.8–3.0 per 100,000 person-years) and prevalence (17 per 100,000), with a substantial proportion of patients experiencing refractory or relapsed disease. Nearly 50% of patients relapse multiple times despite receiving first-line glucocorticoids, second-line CD20 monoclonal antibodies, and multiple conventional immunosuppressants, often becoming dependent on long-term drug therapy. As a result, patients with this otherwise benign disease frequently face a poor quality of life, complicated by thrombotic events, severe infections, and avascular necrosis of the femoral head, with disability or death occurring in 10–30% of cases. There is an urgent clinical need for innovative therapies capable of achieving durable, drug-free remissions.
Clin Cancer Res | Prospective Multicenter Study Led by Dr. Xiaofan Zhu and Dr. Min Ruan Evaluates Venetoclax Plus Reduced-Intensity Chemotherapy in Newly Diagnosed Pediatric AML

Clin Cancer Res | Prospective Multicenter Study Led by Dr. Xiaofan Zhu and Dr. Min Ruan Evaluates Venetoclax Plus Reduced-Intensity Chemotherapy in Newly Diagnosed Pediatric AML

2025.06.12
Acute myeloid leukemia (AML) is a highly heterogeneous clonal malignancy, accounting for approximately 15–20% of pediatric leukemia cases. The current standard first-line induction regimen, known as "3+7," achieves complete remission (CR) rates of approximately 70%. However, about 25% of pediatric patients eventually progress to relapsed/refractory AML (R/R AML), associated with poor prognosis.
N Engl J Med | Lei Zhang’s Team Reports First Clinical Study of Daratumumab in Pediatric Relapsed/Refractory Immune Thrombocytopenia, Demonstrating Significant Efficacy

N Engl J Med | Lei Zhang’s Team Reports First Clinical Study of Daratumumab in Pediatric Relapsed/Refractory Immune Thrombocytopenia, Demonstrating Significant Efficacy

2025.06.12
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antibody-mediated platelet destruction and impaired platelet production, resulting in an increased risk of bleeding. In children, the annual incidence of ITP is approximately 1.9 to 6.4 per 100,000, making it the most common cause of acquired thrombocytopenia in pediatric patients. While most children achieve spontaneous remission either without treatment or following initial therapy, a subset of patients experience recurrent relapses requiring second-line interventions, including rituximab, thrombopoietin receptor agonists (TPO-RAs), splenectomy, and immunosuppressive agents. Due to the lack of prospective clinical trial data in children, selecting optimal second-line therapies remains a considerable clinical challenge.